scholarly journals Incidence, Site and Risk Factor of Post-Transplant Malignancies–Analysis of 771 Renal Transplant Recipients for 40 Years in Japanese Single Center

Author(s):  
Masahiko Okamoto ◽  
Kazuki Sakai ◽  
Shuji Nobori
Open Medicine ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. 322-327 ◽  
Author(s):  
Eglė Dalinkevičienė ◽  
Vytautas Kuzminskis ◽  
Laura Kairevičė ◽  
Rasa Jančiauskienė ◽  
Daimantas Milonas ◽  
...  

AbstractPost-transplant malignancies present an aggressive course and are a significant cause of morbidity and mortality. Tumours of viral ethiology have the greatest risk in renal transplant recipients. Oncogenic effect of immunosuppressive therapy is another major risk factor of post-transplant malignancy. We report cases of three different types of malignancies developed after kidney transplantation: non-Hodgkin’s lymphoma, Kaposi’s sarcoma and germ cell testicular cancer (nonseminoma).


2021 ◽  
Author(s):  
Hari Shankar Meshram ◽  
Vivek Kute ◽  
Himanshu Patel ◽  
Subho Banerjee ◽  
Sanshriti Chauhan ◽  
...  

Nephron ◽  
2021 ◽  
pp. 1-13
Author(s):  
Ana Elena Rodríguez-Rodríguez ◽  
Esteban Porrini ◽  
Mads Hornum ◽  
Javier Donate-Correa ◽  
Raúl Morales-Febles ◽  
...  

Post-transplant diabetes mellitus (PTDM) is a frequent and relevant complication after renal transplantation: it affects 20–30% of renal transplant recipients and increases the risk for cardiovascular and infectious events. Thus, understanding pathogenesis of PTDM would help limiting its consequences. In this review, we analyse novel aspects of PTDM, based on studies of the last decade, such as the clinical evolution of PTDM, early and late, the reversibility rate, diagnostic criteria, risk factors, including pre-transplant metabolic syndrome and insulin resistance (IR) and the interaction between these factors and immunosuppressive medications. Also, we discuss novel pathogenic factors, in particular the role of β-cell function in an environment of IR and common pathways between pre-existing cell damage and tacrolimus-induced toxicity. The relevant role of prediabetes in the pathogenesis of PTDM and cardiovascular disease is also addressed. Finally, current evidence on PTDM treatment is discussed.


Sign in / Sign up

Export Citation Format

Share Document